{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-058258","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2026-08-20T20:25:39+00:00","discovered_at":"2026-08-20T20:27:00.378629+00:00","generated_at":"2026-08-20T20:27:09.661949+00:00","sec_items":["1.01","2.03"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Senti Biosciences subsidiary issues $4.0M convertible notes to Celadon; potential $60M CVR merger pending","bullets":["On Aug 14, 2026, Senti Holdings issued $4.0M principal Senior Secured Convertible Notes to Celadon Partners SPV 24.","Issuance under April 27, 2026 Securities Purchase Agreement; terms referenced from prior 8-Ks filed May 1 and May 26, 2026.","Potential deal: Celadon affiliate to merge with Senti Holdings, issuing CVR worth up to $60M upon SENTI-202 regulatory/sales milestones.","Preliminary proxy statement filed July 21, 2026; definitive proxy will be mailed to stockholders for vote."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-058258","json":"https://secwatch.observer/filing/0001628280-26-058258.json","markdown":"https://secwatch.observer/filing/0001628280-26-058258.md","text":"https://secwatch.observer/filing/0001628280-26-058258.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026058258/0001628280-26-058258-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026058258/snti-20260814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-20T20:27:09.661949+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}